Last $20.09 USD
Change Today -0.11 / -0.54%
Volume 69.0K
OTIC On Other Exchanges
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

otonomy inc (OTIC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $20.45
52 Week Low
08/19/14 - $15.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OTONOMY INC (OTIC)

Related News

No related news articles were found.

otonomy inc (OTIC) Related Businessweek News

No Related Businessweek News Found

otonomy inc (OTIC) Details

Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which is in Phase III clinical trials to treat pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière’s disease; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

37 Employees
Last Reported Date: 08/13/14
Founded in 2008

otonomy inc (OTIC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $535.6K
Chief Financial & Business Officer, Principal...
Total Annual Compensation: $366.0K
Chief Scientific Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2013.

otonomy inc (OTIC) Key Developments

Otonomy, Inc.(NasdaqGM:OTIC) added to NASDAQ Composite Index

Otonomy, Inc. will be added to the NASDAQ Composite Index.

Otonomy Mulls Acquisitions

Otonomy, Inc. is seeking acquisitions using the proceeds from its initial public offering. The company said in a filing, "We may also use a portion of the net proceeds from this offering to in-license, acquire or invest in complementary business, technologies, products or assets."

Otonomy, Inc. Announces Results from Two Phase 3 Trials of AuriPro(TM)

Otonomy, Inc. announced positive results from two identical Phase 3 trials of AuriPro(TM) in a combined total of 532 pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. In both trials, AuriPro achieved the primary efficacy endpoint with statistical significance (p<0.001), showed statistically significant improvements in secondary clinical endpoints and was well tolerated.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OTIC:US $20.09 USD -0.11

OTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OTIC.
View Industry Companies

Industry Analysis


Industry Average

Valuation OTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OTONOMY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at